Core Viewpoint - BillionToOne, Inc. reported strong financial results for Q3 2025, highlighting significant growth in revenue driven by its innovative molecular diagnostics technology, particularly in prenatal and oncology testing [3][5]. Financial Performance - Total revenue for Q3 2025 was $83.5 million, a 117% increase from $38.4 million in Q3 2024 [5][7]. - Prenatal clinical testing revenue reached $74.1 million, up 102% year-over-year, while oncology clinical testing revenue surged to $8.7 million, reflecting a 664% increase [5][7]. - Gross margin improved to 70% in Q3 2025 from 53% in Q3 2024, driven by higher average selling prices (ASP) and reduced costs per test [5][8]. - Operating income was $9.6 million in Q3 2025, compared to an operating loss of $12.6 million in Q3 2024 [9]. Test Volume and ASP - The company accessioned 162,900 tests in Q3 2025, a 51% increase from 107,900 tests in Q3 2024 [4][5]. - The overall ASP increased by 44% to $501 in Q3 2025 compared to $348 in Q3 2024 [6][7]. Cash Flow and IPO - Positive cash flow of $6.2 million was reported in Q3 2025 [5]. - The company raised gross proceeds of $314.0 million from its initial public offering (IPO) [10]. Future Guidance - BillionToOne expects full-year 2025 revenue to be between $293 million and $299 million, indicating growth of 92% to 96% compared to 2024 [11]. - The anticipated revenue for Q4 2025 is projected to be between $84 million and $90 million, representing an 86% to 100% increase year-over-year [11].
BillionToOne Reports Third Quarter 2025 Results